[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8740901A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
PA8740901A1
PA8740901A1 PA20078740901A PA8740901A PA8740901A1 PA 8740901 A1 PA8740901 A1 PA 8740901A1 PA 20078740901 A PA20078740901 A PA 20078740901A PA 8740901 A PA8740901 A PA 8740901A PA 8740901 A1 PA8740901 A1 PA 8740901A1
Authority
PA
Panama
Prior art keywords
organic compounds
compounds
mammals
cancer
composite
Prior art date
Application number
PA20078740901A
Other languages
English (en)
Inventor
Lei Huangshu
G Charest Mark
Chen Zhuoliang
Dai Miao
He Feng
Luu Pham Ly
Kumar Sharma Sushil
Sean Straub Christopher
David Wang Run-Ming
Yang Fan
Zawel Leigh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8740901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8740901A1 publication Critical patent/PA8740901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA (I) O SALES FARMACÉUTICAMENTE ACEPTABLES DEL MISMO, Y AL USO DE ESTOS COMPUESTOS PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS, TALES COMO CÁNCER, EN MAMÍFEROS.
PA20078740901A 2006-08-02 2007-08-02 Compuestos organicos PA8740901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83500006P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PA8740901A1 true PA8740901A1 (es) 2009-04-23

Family

ID=38686647

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078740901A PA8740901A1 (es) 2006-08-02 2007-08-02 Compuestos organicos

Country Status (42)

Country Link
US (3) US8552003B2 (es)
EP (3) EP2537850A1 (es)
JP (1) JP4875749B2 (es)
KR (2) KR101245945B1 (es)
CN (2) CN101511860B (es)
AR (3) AR062159A1 (es)
AU (1) AU2007281230B2 (es)
BR (1) BRPI0714803B8 (es)
CA (1) CA2658525C (es)
CL (1) CL2007002234A1 (es)
CR (2) CR10567A (es)
CU (2) CU23866B1 (es)
DK (1) DK2051990T3 (es)
DO (1) DOP2013000084A (es)
EA (2) EA201401247A1 (es)
ES (2) ES2405947T3 (es)
GE (1) GEP20115251B (es)
GT (2) GT200900019A (es)
HK (2) HK1176613A1 (es)
HN (1) HN2009000214A (es)
HR (1) HRP20130373T1 (es)
IL (3) IL196596A (es)
JO (1) JO2848B1 (es)
MA (1) MA30652B1 (es)
ME (1) ME00585B (es)
MX (1) MX2009001212A (es)
MY (1) MY150460A (es)
NI (2) NI200900081A (es)
NO (1) NO342230B1 (es)
NZ (1) NZ574393A (es)
PA (1) PA8740901A1 (es)
PE (5) PE20110217A1 (es)
PL (1) PL2051990T3 (es)
PT (1) PT2051990E (es)
SI (1) SI2051990T1 (es)
SM (1) SMP200900013B (es)
SV (1) SV2009003160A (es)
TN (1) TN2009000034A1 (es)
TW (1) TWI408133B (es)
UA (1) UA95485C2 (es)
WO (1) WO2008016893A1 (es)
ZA (1) ZA200900371B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
US7456209B2 (en) 2004-07-15 2008-11-25 Tetralogic Pharmaceuticals Corporation IAP binding compounds
US20060167066A1 (en) 2004-12-20 2006-07-27 Genentech, Inc. Pyrrolidine inhibitors of IAP
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5228202B2 (ja) 2006-07-24 2013-07-03 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
RU2009118487A (ru) * 2006-10-19 2010-11-27 Новартис АГ (CH) Органические соединения
MX2009005551A (es) * 2006-11-28 2009-06-08 Novartis Ag Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
EP2089024B1 (en) * 2006-11-28 2011-05-18 Novartis AG Combination of iap inhibitors and flt3 inhibitors
NZ577150A (en) * 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
CL2008001234A1 (es) 2007-04-30 2008-09-22 Genentech Inc Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CA2724720A1 (en) 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
EP2318395A4 (en) 2008-08-02 2011-10-26 Genentech Inc IPA INHIBITORS
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
EP2464347A1 (en) * 2009-08-11 2012-06-20 Novartis AG Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
MX351274B (es) 2009-08-12 2017-10-06 Novartis Ag Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
ES2612472T3 (es) 2010-08-31 2017-05-17 Hanmi Science Co., Ltd. Derivados de quinolina o quinazolina con actividad inductora de apoptosis sobre células
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CN103781776A (zh) 2011-07-13 2014-05-07 诺华股份有限公司 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
CN103814032A (zh) 2011-07-13 2014-05-21 诺华股份有限公司 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物
EP2760446A1 (en) 2011-09-30 2014-08-06 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
WO2013174780A1 (en) * 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
KR20160002850A (ko) 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
SG11201509525XA (en) 2013-06-25 2016-01-28 Inst Medical W & E Hall Method of treating intracellular infection
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
MX2017003227A (es) 2014-09-13 2017-12-04 Novartis Ag Terapias de combinacion de inhibidores de alk.
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
US20200046684A1 (en) 2017-03-31 2020-02-13 Boehringer Ingelheim International Gmbh Anticancer combination therapy
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
WO2020148447A1 (en) 2019-01-17 2020-07-23 Debiopharm International S.A. Combination product for the treatment of cancer
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
EP3947368A4 (en) 2019-04-04 2023-01-04 Dana-Farber Cancer Institute, Inc. CDK2/5 DEGRADING AGENTS AND ASSOCIATED USES
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CA3151770A1 (en) 2019-09-25 2021-04-01 Silvano BRIENZA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AR122515A1 (es) 2020-06-03 2022-09-14 Boehringer Ingelheim Int Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80
AU2021388021A1 (en) 2020-11-24 2023-06-22 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
JPS59141547A (ja) * 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
WO2001090070A2 (en) 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
US7067274B2 (en) * 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
US20100093645A1 (en) * 2004-01-16 2010-04-15 Shaomeng Wang SMAC Peptidomimetics and the Uses Thereof
SE527038C2 (sv) * 2004-02-26 2005-12-13 Ingenjoers N Per Oskar Persson Kassett och apparat för vätskefrysning
CN1926118A (zh) * 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
CN1964970B (zh) * 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
SI1778718T1 (sl) 2004-07-02 2015-01-30 Genentech, Inc. Inhibitorji IAP
US20060167066A1 (en) 2004-12-20 2006-07-27 Genentech, Inc. Pyrrolidine inhibitors of IAP
US20060218632A1 (en) * 2005-03-28 2006-09-28 Cisco Technology, Inc.; Method and system for installing premise equipment
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap
CN101595093A (zh) * 2006-12-07 2009-12-02 诺瓦提斯公司 有机化合物

Also Published As

Publication number Publication date
EA201401247A1 (ru) 2015-07-30
PE20110217A1 (es) 2011-04-01
GEP20115251B (en) 2011-07-11
IL231079A0 (en) 2014-03-31
PE20110218A1 (es) 2011-04-01
BRPI0714803B1 (pt) 2021-03-09
CR20140555A (es) 2015-01-14
BRPI0714803A2 (pt) 2013-05-21
EP2051990A1 (en) 2009-04-29
CN101511860A (zh) 2009-08-19
EP2537850A1 (en) 2012-12-26
ES2559042T3 (es) 2016-02-10
AU2007281230A1 (en) 2008-02-07
NI200900008A (es) 2010-01-07
HK1127616A1 (en) 2009-10-02
US20130005663A1 (en) 2013-01-03
WO2008016893A1 (en) 2008-02-07
TWI408133B (zh) 2013-09-11
KR20090038479A (ko) 2009-04-20
SV2009003160A (es) 2010-04-13
ZA200900371B (en) 2009-12-30
US20140004101A1 (en) 2014-01-02
CN102558165A (zh) 2012-07-11
MA30652B1 (fr) 2009-08-03
ES2405947T3 (es) 2013-06-04
NO20090878L (no) 2009-04-27
KR101087878B1 (ko) 2011-11-30
SMP200900013B (it) 2010-01-19
DK2051990T3 (da) 2013-05-13
AU2007281230B2 (en) 2011-09-08
SI2051990T1 (sl) 2013-06-28
TN2009000034A1 (en) 2010-08-19
IL231079A (en) 2015-02-26
MY150460A (en) 2014-01-30
PE20110220A1 (es) 2011-04-11
PT2051990E (pt) 2013-05-10
UA95485C2 (uk) 2011-08-10
MX2009001212A (es) 2009-02-11
NZ574393A (en) 2012-03-30
EA200900227A1 (ru) 2009-08-28
AR062159A1 (es) 2008-10-22
HN2009000214A (es) 2011-10-11
CU24004B1 (es) 2014-06-27
IL196596A0 (en) 2009-11-18
PE20080951A1 (es) 2008-09-11
JP4875749B2 (ja) 2012-02-15
EA021671B1 (ru) 2015-08-31
CA2658525C (en) 2013-02-19
JO2848B1 (en) 2014-09-15
HK1176613A1 (en) 2013-08-02
CA2658525A1 (en) 2008-02-07
EP2537846B1 (en) 2015-09-16
PL2051990T3 (pl) 2013-07-31
TW200815399A (en) 2008-04-01
HRP20130373T1 (en) 2013-05-31
CU23866B1 (es) 2013-03-27
CU20090017A7 (es) 2011-03-21
GT200900019AA (es) 2015-11-24
CN102558165B (zh) 2014-08-13
EP2537846A1 (en) 2012-12-26
EP2051990B1 (en) 2013-02-06
NI200900081A (es) 2010-01-07
DOP2013000084A (es) 2013-06-15
US8552003B2 (en) 2013-10-08
ME00585A (en) 2011-12-20
JP2009545613A (ja) 2009-12-24
ME00585B (me) 2011-12-20
PE20110224A1 (es) 2011-04-05
CR10567A (es) 2009-02-18
IL236883A0 (en) 2015-03-31
AR112816A2 (es) 2019-12-18
SMAP200900013A (it) 2009-05-11
GT200900019A (es) 2010-06-01
BRPI0714803B8 (pt) 2021-05-25
US20110065726A1 (en) 2011-03-17
CN101511860B (zh) 2013-05-01
IL196596A (en) 2014-09-30
CU20110027A7 (es) 2011-12-28
AR110313A2 (es) 2019-03-13
CL2007002234A1 (es) 2008-06-13
NO342230B1 (no) 2018-04-23
KR101245945B1 (ko) 2013-03-22
KR20110030667A (ko) 2011-03-23
US8546336B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
PA8740901A1 (es) Compuestos organicos
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
PA8841901A1 (es) Compuestos orgánicos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
ECSP109934A (es) Compuesto - 946
CL2008001213A1 (es) Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer.
CO6640285A2 (es) 5-alquinil-pirimidinas
AR091837A1 (es) Compuestos para inmunoterapia dirigida
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
BR112012011086A2 (pt) uso de betanecol para o tratamento de xerostomia
GT201400111A (es) Triazolopiridinas sustituidas
CR20110339A (es) Compuestos útiles para inhibir chk1
CR20120213A (es) Métodos para el tratamiento del cáncer usando antagonistas de notch
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2008001728A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
SV2011003784A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2011001850A1 (es) Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.